GammaDelta Therapeutics
GammaDelta Therapeutics is a London-based clinical-stage biotech founded in 2016 developing proprietary gamma delta (γδ) T-cell therapies for cancer and related diseases, backed by Abingworth, Cancer Research Horizons, King's College London, and The Francis Crick Institute.
- Company typePrivate
- Founded2016
- HeadquartersLondon, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What GammaDelta Therapeutics does
GammaDelta Therapeutics is a London, UK-based clinical-stage biotechnology company founded in 2016 developing therapies based on gamma delta (γδ) T-cells, an alternative T-cell modality distinct from conventional alpha-beta T-cell and CAR-T approaches. The company is building a proprietary platform around γδ cell biology — a niche of innate-like lymphocytes with potential applications in oncology and other diseases — and has expanded its capabilities through the May 2018 acquisition of Lymphact, a peer developer in the γδ space. The founding scientific team is anchored by Adrian Hayday as co-founder, with operational leadership including Sandra Van Wetering as VP of Process Science and Manufacturing, indicating investment in CMC and scale-up infrastructure required for cell therapy development.
The company operates as a privately held for-profit biotech (101-250 employees) with a translational research base in the London bioscience cluster. Initial capital formation in September 2016 brought together commercial life-sciences investor Abingworth with embedded translational partners Cancer Research Horizons, King's College London, and The Francis Crick Institute — a structure typical of UK academic spinouts that combines venture capital with institutional R&D capability. The business model is consistent with a development-stage cell therapy company: value is created through advancing proprietary γδ platform candidates toward clinical proof-of-concept, with future monetization likely via licensing, partnership, or M&A rather than direct commercialization.
The provided source data does not disclose specific γδ product candidates, target indications, clinical trial milestones, or commercial partnerships, and most quantitative signals in the input relate to broader market context (global T-cell therapy market projected at USD 85.61 billion by 2030 at 45.31% CAGR per source) or to Takeda Pharmaceuticals rather than GammaDelta directly. As a result, the company's current pipeline maturity, preclinical-to-clinical transition status, and intellectual property breadth cannot be reliably characterized from the input.
GammaDelta Therapeutics firmographics
Firmographics- Name
- GammaDelta Therapeutics
- Website
- https://gammadeltatx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- GammaDelta Therapeutics is a London-based clinical-stage biotech founded in 2016 developing proprietary gamma delta (γδ) T-cell therapies for cancer and related diseases, backed by Abingworth, Cancer Research Horizons, King's College London, and The Francis Crick Institute.
- Ownership category
- akta.pro rank
GammaDelta Therapeutics industry classification
Industry- Product category
- Cell Therapy / Gamma Delta T-cell Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where GammaDelta Therapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
GammaDelta Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels5 records
GammaDelta Therapeutics product offering
Product offeringCore offering
GammaDelta Therapeutics is a clinical-stage biotechnology company developing immunotherapies based on gamma delta (γδ) T-cells. The company is focused on harnessing the unique properties of γδ T-cells to develop novel cell therapies targeting cancer and other serious diseases, leveraging its proprietary cell platform and process science capabilities.
Differentiator
Problem solved
Functional benefit
Companies that use GammaDelta Therapeutics
Customer profileIdeal customer profiles1 record
GammaDelta Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GammaDelta Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Takeda Pharmaceuticalsnotable exit from cell therapy sectorTakeda withdrew from cell therapy R&D following disappointing clinical results and recorded a $395 million impairment charge. This strategic recalibration is cited as part of a broader bifurcation in the cell therapy market, where some companies exit complex modalities while others build foundational platforms for next-generation therapies.
Scale indicators7 records
Recent moves3 records
Expansion highlights4 records
GammaDelta Therapeutics competitors and assessment
Company assessmentRegional players
- Pharming Technologies: European-listed biotech developing biological therapies for rare diseases; comparable only as a European-listed specialty biotech peer in capital markets and partnership dynamics, not in modality.
Direct peers
- Adicet Bio: Clinical-stage biotech developing allogeneic gamma delta T-cell therapies for cancer, the closest direct competitor to GammaDelta's γδ platform in both modality and target indications.
- TC BioPharm: Developer of gamma delta T-cell-based cell therapies for oncology, sharing GammaDelta's core scientific premise and modality.
- Adaptimmune Therapeutics: Engineered T-cell therapy company developing TCR-T cell therapies for solid tumors; directly comparable as a T-cell receptor-based cancer cell therapy developer.
- Immatics: Clinical-stage TCR and adoptive cell therapy company developing engineered T-cell receptor immunotherapies for cancer, a peer in the broader engineered T-cell therapy space.
Broad incumbents
- Allogene Therapeutics: Pioneer in allogeneic 'off-the-shelf' CAR-T cell therapies; comparable to GammaDelta as an allogeneic cell therapy developer with broader pipeline scope.
- Cellectis: Clinical-stage gene-edited allogeneic CAR-T platform company; comparable to GammaDelta as a developer of engineered allogeneic cell therapies with enabling gene-editing capabilities.
- CRISPR Therapeutics: Clinical-stage gene editing company developing both gene-edited cell therapies (e.g., allogeneic CAR-T) and gene therapies; comparable in the broader engineered cell therapy category.
Emerging players
- Caribou Biosciences: Developer of allogeneic CAR-T cell therapies using CRISPR gene editing; an emerging player in the allogeneic cell therapy space adjacent to GammaDelta's γδ platform.
Others
- Takeda Pharmaceuticals: Global pharmaceutical company that previously invested in cell therapy R&D and recorded a USD 395M impairment upon exit; relevant as a potential strategic partner or acquirer, despite having exited the modality.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
GammaDelta Therapeutics social profiles
Digital presenceGammaDelta Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
GammaDelta Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
GammaDelta Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GammaDelta Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GammaDelta Therapeutics
What does GammaDelta Therapeutics do?
GammaDelta Therapeutics is a clinical-stage biotechnology company developing immunotherapies based on gamma delta (γδ) T-cells. The company is focused on harnessing the unique properties of γδ T-cells to develop novel cell therapies targeting cancer and other serious diseases, leveraging its proprietary cell platform and process science capabilities.
Is GammaDelta Therapeutics a public or private company?
GammaDelta Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was GammaDelta Therapeutics founded?
GammaDelta Therapeutics was founded in 2016. It employs 101 to 250 people.
Where is GammaDelta Therapeutics based?
GammaDelta Therapeutics is headquartered in London, United Kingdom, in the Europe region.
Who are GammaDelta Therapeutics's main competitors?
Pharming Technologies is listed as a regional player. Direct peers are Adicet Bio, TC BioPharm, Adaptimmune Therapeutics and Immatics. Broad incumbents are Allogene Therapeutics, Cellectis and CRISPR Therapeutics. Caribou Biosciences is listed as an emerging player. Takeda Pharmaceuticals is listed as an others.
Does GammaDelta Therapeutics have an API?
No public API is recorded for GammaDelta Therapeutics.
What industry is GammaDelta Therapeutics in?
GammaDelta Therapeutics's product category is Cell Therapy / Gamma Delta T-cell Immunotherapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.